



PALLA PHARMA

ASX ANNOUNCEMENT

Monday 30 August 2021

Revised Half Year Reporting Timetable and Results Presentation

Further to the ASX announcement of 18 August 2021, Palla Pharma Limited (ASX:PAL) today is advising of a revised half year reporting timetable which supersedes the previously announced intention to release its results for the half-year ended 30 June 2021 today.

The Company regrets any inconvenience that the changes in the timeline may cause for interested parties. The changed timeline is necessary due to the timing of raising incremental debt capital to fund the continued growth of the business which has impacted the ability to complete the half year financial report and allow the Company's auditor sufficient time to complete their review.

The revised timeline for the Company's half-year results reporting is as follows:

- Tuesday 31 August 2021 – lodgement of Appendix 4D and unreviewed accounts for the half-year ended 30 June 2021;
- On or before Thursday 9 September 2021 – lodgement of reviewed accounts for the half-year ended 30 June 2021; and
- Wednesday 22 September 2021 – Half Year Results Presentation and Investor Update, including introduction to new Chief Executive Officer Giles Moss.

The Company will be relying on relief provided by ASIC Corporations (Extended Reporting and Lodgement Deadlines—Listed Entities) Instrument 2020/451 which extends the lodgement deadline for listed entities to lodge their half yearly reports by allowing up to one additional month.

This announcement has been authorised for release by the Board of Directors.

For more information please contact:

Simon Moore

Chairman
Palla Pharma Limited
+61 3 9301 0800

Adrian Mulcahy

Investor Relations
Market Eye
+61 438 630 422 or ir@pallapharma.com

Brendan Middleton

Interim CEO
Palla Pharma Limited
+61 3 9301 0800

Tristan Everett

Media Enquiries
Market Eye
+61 403 789 096 or media@pallapharma.com

Palla Pharma Limited

PO Box 2139 Melbourne, VIC 3001, Australia

T +61 3 9301 0800 / **F** +61 3 9301 0899 / **W** pallapharma.com / **E** info@pallapharma.com



PALLA PHARMA

About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.

Palla Pharma Limited

PO Box 2139 Melbourne, VIC 3001, Australia

T +61 3 9301 0800 / **F** +61 3 9301 0899 / **W** pallapharma.com / **E** info@pallapharma.com